

Editorial

New Insights of Probiotics for Obesity and its Metabolic Disorders: Big Hope from the Small Micro-organisms

Ramesh Pothuraju* and Minaxi

Department of Animal Biochemistry and Dairy Chemistry, ICAR-National Dairy Research Institute, India

*Corresponding author: Ramesh Pothuraju, Department of Animal Biochemistry, ICAR-National Dairy Research Institute, Karnal-132001, Haryana, India

Received: May 23, 2016; **Accepted:** May 30, 2016;

Published: May 31, 2016

Editorial

Excessive caloric intake and less physical expenditure are contributing the obesity and its associated metabolic disorders. The calories which come through the diet, accumulated in the adipose tissue as Triglycerides (TGs) and stored in the form of lipid droplets. Further, these TGs are breakdown into the Free Fatty Acids (FFAs) and enter into the circulation during obesity, insulin resistance and diabetes [1]. Increased circulatory FFAs further stores in the non-adipose tissue *viz.*, muscle, liver & kidney and may contribute obesity associated metabolic diseases [2]. Ample of storage of lipids in the adipose tissue increase its size and makes them vulnerable for the infiltration of macrophages and further leads to low grade inflammation [3]. Recent evidence suggested that the pharmacological and surgical interventions are not effective for treating obesity [4]. So, people are keen interest towards alternative therapies like probiotics, prebiotics and herbal supplementations as natural medications with little or no side effects. According to the FAO/WHO (2001), probiotics are “live micro-organisms which when administered in adequate amounts confer health benefits to the host” [5]. The healthy human gut microbiota comprises 10^{12} microbes with major phyla *Bacteroidetes* and fewer *Firmicutes*, however, dysbiosis of aforementioned phyla occurs in obesity [6,7]. Several studies are demonstrated that probiotics (lactobacilli and bifidobacteria species) play a significant role in animal and human studies.

Gut microbiota and its effects on human metabolism reported by the several researchers. Lactobacilli and bifidobacteria species are predominantly studied for their anti-obesity effects [8,9]. Reports suggesting that oral administration of *Lactobacillus rhamnosus* PL60/PL62 and GG into obese mice showed a significantly reduction of body weight, visceral fat and liver biomarker enzymes [10-12]. In our previous study, we demonstrated that probiotic dahi (traditional Indian fermented milk) containing *Lactobacillus casei* had a significant reduction in body weight, fasting blood glucose levels, epididymal fat tissue in high fat diet fed C57BL/6 mice [8]. In other recent studies, milk fermented by *Lactobacillus rhamnosus/plantarum* alone or in combination of herbal supplementation observed lowering of hyperglycemic and hyperlipidemic effects in diet induced obese mice. In addition, a significant decrease in the adipocyte cell size and pro-inflammatory cytokines [13,14].

The intestinal micro-organisms are utilized the indigestible carbohydrates for the synthesis of volatile fatty acids like acetate, propionate and butyrate [15]. These Short Chain Fatty Acids (SCFAs) are utilized by the intestinal cells as energy source and some other contributes to the activation of fatty acid oxidation pathways to decrease adiposity [16-18]. Administration of mixed culture of probiotics VSL#3 (*Streptococcus thermophilus*, *Bifidobacterium* and *Lactobacillus*) in obese mice (Lep ob/ob) had shown reduction in the body weight and feed intake through butyrate via stimulating the secretion of glucagon like peptide levels from intestinal cells [19].

Due to adequate storage of the lipids in the adipose tissue also increase the size and results in less vascularization (fewer blood vessels); hypoxia which contributes for recruiting immune cells (macrophages) [3]. Infiltration of macrophages responsible for the release of pro-inflammatory cytokines (tumor necrosis factor-alpha and interleukins) in the adipose tissue. Furthermore, low grade inflammation also occurs by the release of Lipopolysaccharides (LPS) from the Gram negative bacteria and referred as metabolic endotoxemia [20]. These LPS are initially damage to the intestinal tight junction proteins (eg: ZO-1, claudin-2 and occludin) and enters into the circulation where binds to its receptors located on the immune cells to promote inflammation [21,22]. The cocktail of VSL#3 probiotics, *Lactobacillus plantarum* MB452 and *Akkermansia muciniphila* were reported to be an improvement in the intestinal permeability damage by adhering to its membrane in obese and diabetic animals [23,24]. In addition, *bifidobacterium* selectively showed a positive effect on intestinal tight junction proteins in the presence of prebiotic oligofructose by the production of SCFAs [25]. In case of clinical studies very few reports are available in this regard. Studies on milk fermented by *Lactobacillus gasseri* SBT2055 (200g/day, 10^8 cfu/day) had shown a decrease in the body weight gain, visceral fat mass and serum TGs levels in obesity tendency human subjects [26,27,28]. A combination of several probiotic species (*Bifidobacterium bifidum* W23, *Bifidobacterium lactis* W51 *Enterococcus faecium* W54, *Lactobacillus acidophilus* W22, *Lactobacillus brevis* W63 and *Lactococcus lactis* W58) were also improves tight junction proteins in endurance trained humans [29].

However, some of the contradictory results are also reported with the lactobacilli and other organisms. These results indicated that these micro-organisms are mainly strain dependent, type of diet and animal model used. In near future, more studies are required in the field of probiotics in clinical applications to cure obesity and its associated metabolic disorders.

References

1. Yin YN, Yu QF, Fu N, Liu XW, Lu FG. Effects of four Bifidobacteria on obesity in high-fat diet induced rats. *World J Gastroenterol*. 2010; 16: 3394-3401.
2. Reaven GM. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. *Circulation*. 2002; 106: 286-288.

3. Sears IB, MacGinnitie MA, Kovacs LG, Graves RA. Differentiation dependent expression of the brown adipocyte uncoupling protein gene: regulation by peroxisome proliferator-activated receptor gamma. *Mol Cell Biol*. 1996; 16: 3410-3419.
4. Glenny AM, Oimeara S, Melville A, Sheldon TA, Wilson C. The treatment and prevention of obesity; a systematic review of the literature. *Int J Obes Relat Metab Disord*. 1997; 21: 715-737.
5. Food and Agriculture Organization of the United Nations/World Health Organization (FAO/WHO). Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. 2001.
6. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. *Proc Natl Acad Sci USA*. 2005; 102: 11070-11075.
7. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. *Nature*. 2006; 444: 1022-1023.
8. Rather SA, Pothuraju R, Sharma RK, De S, Mir NA, Jangra S. Anti-obesity effects of feeding probiotic dahi containing *Lactobacillus casei* NCDC 19 in high-fat diet-induced obese mice. *Int J Dairy Tech*. 2014; 67: 504-509.
9. Kondo S, Xiao JZ, Satoh T, Odamaki T, Takahashi S, Sugahara H, et al. Anti-obesity effects of *Bifidobacterium breve* strain B-3 supplementation in a mouse model with high-fat diet-induced obesity. *Biosci Biotechnol Biochem*. 2010; 74: 1656-1661.
10. Lee HY, Park JH, Seok SH, Baek MW, Kim DJ, Lee KE. Human originated bacteria, *Lactobacillus rhamnosus* PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice. *Biochim Biophys Acta*. 2006; 1761: 736-744.
11. Lee K, Paek K, Lee HY, Park JH, Lee Y. Anti-obesity effect of trans-10, cis-12-conjugated linoleic acid-producing *Lactobacillus plantarum* PL62 on diet-induced obese mice. *J Appl Microbiol*. 2007; 103: 1140-1146.
12. Ji YS, Kim HN, Park HJ, Lee JE, Yeo SY, Yang JS, et al. Modulation of the murine microbiome with a concomitant anti-obesity effect by *Lactobacillus rhamnosus* GG and *Lactobacillus sakei* NR28. *Benefic Microbes*. 2012; 3: 13-22.
13. Pothuraju R, Sharma RK, Chagalamarri J, Kavadi PK, Jangra S. Influence of milk fermented with *Lactobacillus rhamnosus* NCDC 17 alone and in combination with herbal ingredients on diet induced adiposity and related gene expression in C57BL/6J mice. *Food & Funct*. 2015; 6: 3576-3584.
14. Pothuraju R, Sharma RK, Kumar Kavadi P, Chagalamarri J, Jangra S, Bhakri G, et al. Anti-obesity effect of milk fermented by *Lactobacillus plantarum* NCDC 625 alone and in combination with herbs on high fat diet fed C57BL/6J mice. *Benef Microbes*. 2016; 7: 375-381.
15. Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI. Human nutrition, the gut microbiome and the immune system. *Nature*. 2011; 474: 327-336.
16. Lin HV, Frassetto A, Kowalik EJ, Nawrocki AR, Lu MM, Kosinski JR, et al. Butyrate and Propionate Protect against Diet-Induced Obesity and Regulate Gut Hormones via Free Fatty Acid Receptor 3-Independent Mechanisms. *PLoS One*. 2012; 7: e35240.
17. Yamashita H, Fujisawa K, Ito E, Idei S, Kawaguchi N, Kimoto M, et al. Improvement of obesity and glucose tolerance by acetate in Type 2 diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats. *Biosci Biotechnol Biochem*. 2007; 71: 1236-1243.
18. Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. *Diabetes*. 2009; 58: 1509-1517.
19. Yadav H, Lee JH, Lloyd J, Walter P, Rane SG. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. *J Biol Chem*. 2013; 288: 25088-25097.
20. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic Endotoxemia Initiates Obesity and Insulin Resistance. *Diabetes*. 2007; 56: 1761-1772.
21. Haziot A, Chen S, Ferrero E, Low MG, Silber R, Goyert SM. The monocytic differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. *J Immunol*. 1988; 141: 547-552.
22. Goyert SM, Ferrero E, Rettig WJ, Yenamandra AK, Obata F, Le Beau MM. The CD14 monocyte differentiation antigen maps to a region encoding growth factors and receptors. *Science*. 1988; 239: 497-500.
23. Anderson RC, Cookson AL, McNabb WC, Park Z, McCann MJ, Kelly WJ, et al. *Lactobacillus plantarum* MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation. *BMC Microbiol*. 2010; 10: 316.
24. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, et al. Cross-talk between *Akkermansia muciniphila* and intestinal epithelium controls diet-induced obesity. *Proc Natl Acad Sci USA*. 2013; 110: 9066-9071.
25. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, et al. Selective increases of bifidobacteria in gut microflora improve high-fat diet-induced diabetes in mice through a mechanism associated with endotoxaemia. *Diabetologia*. 2007; 50: 2374-2383.
26. Kadooka Y, Sato M, Imaizumi K, Ogawa A, Ikuyama K, Akai Y, et al. Regulation of abdominal adiposity by probiotics (*Lactobacillus gasseri* SBT2055) in adults with obese tendencies in a randomized controlled trial. *Eur J Clin Nutr*. 2010; 64: 636-643.
27. Kadooka Y, Sato M, Ogawa A, Miyoshi M, Uenishi H, Ogawa H, et al. Effect of *Lactobacillus gasseri* SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial. *Br J Nutr*. 2013; 110: 1696-1703.
28. Ogawa A, Kadooka Y, Kato K, Shirouchi B, Sato M. *Lactobacillus gasseri* SBT2055 reduces post prandial and fasting serum non-esterified fatty acid levels in Japanese hypertriglycerolemic subjects. *Lipids Health Dis*. 2014; 13: 36.
29. Lamprecht M, Bogner S, Schipping G, Steinbauer K, Fankhauser F, Hallstroem S, et al. Probiotic supplementation affects markers of intestinal barrier, oxidation and inflammation in trained men; a randomized, double-blinded, placebo-controlled trial. *J Int Soc Sports Nutr*. 2012; 9: 45.